skip to primary navigationskip to content

People

Emily Fisher

Emily graduated from Newcastle University in 2012 with an MChem in Medicinal Chemistry. As part of her degree she undertook an industrial placement with Piramal Healtcare working on large-scale production chemistry. Her final year project was undertaken with Michael Carroll investigating the steric and electronic control of the fluorination of diaryliodonium salts. After graduating she worked for Fine Organics Ltd again working on large-scale production chemistry.

Emily started her PhD in the MICL in October 2013 where she is developing radiotracers for imaging alpha-synuclein.

Martin Fisher

Martin graduated with a 1st class MChem degree from University of Leeds 2007. He studied for his PhD under the supervision of Prof. Adam Nelson at the University of Leeds working towards an integrated in silico design and diversity-oriented synthesis approach to generate novel platensimycin analogues. Since graduating in 2011 Martin has worked at PolyTherics developing antibody-based anti-cancer agents and as a post doc with Dr Robin Bon at the University of Leeds developing novel imaging agents for imaging cardiovascular disease using MRI.

 

Martin joined the MICL in 2014 as part of a 4 year post doctoral training program in radiochemistry to develop imaging agents for neuropsychiatric disease that will include a 5 month secondment working in Vic Pike’s group at the NIH in the USA.

Lindsay McMurray

Lindsay received her MSci in Natural Sciences from St Catharine’s College, University of Cambridge in 2008. Following this, she continued her PhD studies at the University of Cambridge working in the group of Prof. Matthew Gaunt developing novel copper-catalysed arylation reactions and metal-catalyzed C–H functionalisation strategies for the synthesis of the natural products.

Since completing her PhD in 2012, Lindsay worked for the healthcare consultancy firm IMSCG before commencing a 4 year post doctoral training program at the MICL in February 2014 working towards the development of novel radiotracers for imaging neurodegeneration.

Selena Milicevic Sephton

Selena obtained her BSc degree from the University of Belgrade (Serbia) in 2003 and PhD in Organic Chemistry from Oregon State University (USA) in 2008 under the supervision of Prof. Paul R. Blakemore. She then worked as a postdoctoral researcher in Prof. Scott E. Denmark’s group at the University of Illinois at Urbana-Champaign (USA) before moving to the Swiss Federal Institute of Technology (ETH Zurich, Switzerland) in 2010 to work in the group of Prof. Simon M. Ametamey on the development of novel PET radiotracers for imaging mGlu­5 resulting in identification and application of clinical candidate [18F]-PSS232.

 

Selena joined the MICL in 2013, under supervision of Prof. Franklin I. Aigbirhio where she works on the development of novel PET radiotracers for imaging cerebral protein synthesis.

Mitja Kovac

Mitja received his MPharm from Faculty of Pharmacy in Ljubljana (Slovenia) in 2006. He then specialised as a community pharmacist and worked as associate lecturer of pharmacology in Maribor (Slovenia). He obtained his PhD in 2013 jointly at the Faculty of Pharmacy in Ljubljana (Slovenia) and Tours (France) developing fluorinated benzovesamicol derivatives as potential radioglands for the vesicular acetylcholine transporter.

 

Mitja joined the MICL in September 2013, as a Research Associate developing novel PET radiotracers for imaging Tau pathology and neurodegeneration in Alzheimer's disease.

Laurent B

Laurent graduated in Chemical Sciences from the University of Liège (Belgium) in 2000. Including a final year project, under the supervision of Professor Andre Luxen, on the radiosynthesis of [11C]benzophenone from [11C]CO in a palladium-mediated labelling reaction between an iodonium salt and an organotin compound.


Supported by a funding from Lafon (France), Laurent did a PhD on [11C]CO radiochemistry where he developed a semi-automated system for carbonylation reactions for the production of [11C]-labelled ketones, esters and amides from [11C]CO. During this time he also established a five steps radiosynthesis of [11C]modafinil from [11C]benzophenone.
Shortly after his PhD, Laurent joined Dr John Clark’s group at the Wolfson Brain Imaging Centre to work under the supervision of Professor Franklin Aigbirhio in the MICL.

Dave Williamson

Dave gained a BSc in Physiology/Pharmacology from Hatfield Polytechnic in 1989 and immediately joined the Merck Sharp and Dohme Neuroscience Research Centre in Harlow. Dave spent 2 years in the Department of Behavioral Pharmacology conducting preclinical operant tests of cognition, then moved to the newly created In Vivo Pharmacology Group where he worked on a number of Neuroscience projects such as migraine, pain, depression schizophrenia and Alzheimer’s disease.  During his time at the Neuroscience Research Centre Dave gained a PhD in 2000 after developing a novel preclinical Migraine Model.

 

Dave joined the Wolfson Brain Imaging Centre in 2007 as the Head of PET Biology, with responsibility for conducting in vivo imaging mostly in preclinical models of Stroke.  More recently, the emphasis has turned to dementia and he is currently involved in the development of novel PET tracers targeted at the pathology of Alzheimer’s disease using preclinical imaging methods and in vitro techniques including human tissues.  

Steven Kealey

Steven studied Chemistry at Imperial College London, completing his MSci degree in 2004 and his PhD, under the supervision of Prof Nick Long, in 2008.

 

He has since worked as a postdoctoral researcher at Imperial College London and the University of Bath, in collaboration with the Clinical Imaging Centre at Hammersmith Hospital. In 2011 he was awarded an Excellence Fellowship at the Institute of Psychiatry, King’s College London, based at the Imanova Centre for Imaging Sciences. Steve joined the Aigbirhio group in September 2015 to work on the development of HER2 radiotracers as biomarkers for breast cancer.

 

His research interests include novel radiolabelling methodologies and the development and evaluation of PET radiotracers for in vivo imaging of neurodegenerative and psychiatric disorders and for application in oncology.

Ole Tietz

Ole obtained his BSc in Chemistry and MRes in Biomedical Chemistry from Imperial College London in 2010. He went on to study under the supervision of Prof. Frank Wuest at the University of Alberta (Canada) and obtained his PhD in Experimental Oncology in 2015. During his PhD studies, Ole worked on the development of novel PET radiotracers for the molecular imaging of cyclooxygenase-2 (COX-2) in cancer. His research interests include the development and synthesis of novel radiotacers and their in vivo evaluation for applications in oncology and neuroscience.

 

Ole joined the MICL in September 2015 and works on the development of novel PET tracers for imaging neurodegeneration.